GSK has been granted a patent for methods of treating lung cancer by administering a specific dosage of TIM-3 binding agents. The patent outlines a treatment regimen involving a flat dose of 300 mg every 3 weeks, along with an anti-PD-1 antibody. GlobalData’s report on GSK gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights GSK plc - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on GSK, Human telomerase RT biomarker was a key innovation area identified from patents. GSK's grant share as of February 2024 was 46%. Grant share is based on the ratio of number of grants to total number of patents.

Treatment of lung cancer with tim-3 binding agents

Source: United States Patent and Trademark Office (USPTO). Credit: GSK plc

A recently granted patent (Publication Number: US11926665B2) outlines a method for treating lung cancer in human subjects. The method involves administering a flat dose of 300 mg of an anti-TIM-3 antibody and a flat dose of 500 mg of an anti-PD-1 antibody every 3 weeks. The anti-TIM-3 antibody consists of specific heavy and light chain variable domains, while the anti-PD-1 antibody includes distinct heavy and light chain sequences. Additionally, the treatment may include the administration of a chemotherapeutic agent to the patient.

Furthermore, the patent details the specific administration process, suggesting that the anti-TIM-3 antibody should be given to the patient before the anti-PD-1 antibody, with a recommended time gap of either 30 or 45 minutes. Both antibodies are to be administered intravenously, with the anti-TIM-3 antibody potentially being part of a composition for intravenous infusion. The method is particularly focused on treating non-small cell lung cancer in human subjects, emphasizing the importance of the sequence and dosage of the antibodies along with the potential inclusion of a chemotherapeutic agent in the treatment regimen.

To know more about GlobalData’s detailed insights on GSK, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies